Pharmapack Europe experts expect smaller and medium European packaging companies to grow or be acquired.
Ahead of Pharmapack Europe 2023, taking place on Feb. 1–2, 2023, the event’s panel of experts predict increased consolidations in 2023, driven by supply chain concerns and big pharma preferences. A report to be published at the show, foresees continued challenges ahead for smaller and medium-sized packaging companies that are likely to face significant competitive pressures. The report highlights that many companies are looking to sell products globally, with multiple regulatory burdens and divergent standards. Companies turning over €20 million or less are more likely to be potential acquisition targets.
“Pharma customers like to have suppliers they can reply upon for more than single components (e.g.. cap, bottles, etc.) and increasingly want providers that can provide complete solutions,” said Gregor Nischer, MP corporate finance GmbH managing partner, in a press release. “At the same time, regulations are becoming more complex, and small companies don't have the necessary resources, meaning the development of products is becoming prohibitively expensive.”
The event, which is at the center of pharma’s packaging and drug delivery devices industry, will take place at the Paris Expo, Porte de Versailles (Hall 7.2) and will see 5500 attendees and more than 300 companies.
Source: Pharmapack
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.